EGF and neoplasm: An anti-tumor treatment cycle of 4 mg·kg−1 EGF(scFv)–MAP intravenously administered to mice at 11 days after tumor challenge resulted in a significant reduction in tumor growth when compared to the control group that received phosphate-buffered saline (PBS) [18].